文献速递关节外科

Mark Coventry奖:髌股关节置换术在活动度与早期患者报告结局方面优于全膝关节置换术

The Mark Coventry Award: Patellofemoral Arthroplasty Results in Better Range of Movement and Early Patient-reported Outcomes Than TKA.
PubMed 文献 · Clin Orthop Relat Res · 2018-01-01

这项盲法随机对照试验纳入100例孤立性髌股骨关节炎患者,比较髌股关节置换术(PFA)与全膝关节置换术(TKA)术后2年结局。PFA组在SF-36躯体疼痛、躯体功能、KOOS症状和OKS的2年曲线下面积均优于TKA组,活动度恢复更好,并发症数量无差异。

要点

  • PFA组术后2年SF-36躯体疼痛AUC为9.2个月,优于TKA组的6.5个月(p=0.008)。
  • 术后2年PFA组活动度较基线变化-3°,TKA组为-10°(p=0.010)。
  • 两组并发症数量无差异,PFA组2年内有2例翻修。

核心结论

  • 对于孤立性髌股骨关节炎,PFA患者术后2年内整体膝关节特异性生活质量优于TKA患者。
  • 术后2年时仅KOOS功能维度在PFA与TKA组间存在差异,其他患者报告结局维度两组无差异。
  • PFA患者恢复更快,术后9个月内功能结局优于TKA;PFA患者恢复术前活动度,而TKA患者术后2年活动度较术前丢失10°。
  • 两组并发症数量无差异。

研究设计与样本

  • 盲法随机对照试验,2007年至2014年纳入100例有致残症状且为孤立性髌股疾病的患者,随机分配至PFA或TKA组。
  • 第一年对患者、治疗师、初级保健医生等设盲,对评估者为准盲法。
  • 术后前2年进行4次临床随访并完成6套问卷,主要结局为SF-36躯体疼痛。
  • PFA组平均纳入年龄64岁(SD 8.9),女性占77%(77/100)。

主要发现

  • 术后2年SF-36躯体疼痛AUC:PFA组9.2个月(SD 4.3) vs TKA组6.5个月(SD 4.5),p=0.008。
  • 术后2年SF-36躯体功能AUC:PFA组6.6个月(SD 4.8) vs TKA组4.2个月(SD 4.3),p=0.028。
  • 术后2年KOOS症状AUC:PFA组5.6个月(SD 4.1) vs TKA组2.8个月(SD 4.5),p=0.006。
  • 术后2年OKS AUC:PFA组7.5个月(SD 2.7) vs TKA组5.0个月(SD 3.6),p=0.001。
  • 术后6个月SF-36躯体疼痛改善:PFA组38(SD 24) vs TKA组27(SD 23),p=0.041;术后2年改善分别为39(SD 24) vs 33(SD 22),p=0.199。

关键数值与推荐

  • 术后6个月KOOS症状改善:PFA组24(SD 20) vs TKA组7(SD 21),p<0.001;术后2年改善分别为27(SD 19) vs 17(SD 21),p=0.023。
  • 术后4个月活动度较基线变化:PFA组-7°(SD 13°) vs TKA组-18°(SD 14°),p<0.001。
  • 术后1年活动度较基线变化:PFA组-4°(SD 15°) vs TKA组-11°(SD 12°),p=0.011。
  • 术后2年活动度较基线变化:PFA组-3°(SD 12°) vs TKA组-10°(SD 12°),p=0.010。
  • 术后2年内翻修:PFA组2例(1例翻修为新PFA,1例翻修为TKA)。

临床怎么用

  • 对于孤立性髌股骨关节炎,PFA可获得比TKA更好的术后2年膝关节特异性生活质量和活动度恢复。
  • PFA患者恢复更快,术后9个月内功能结局优于TKA。
  • 两组并发症数量无差异。

局限性

  • PFA组4%(2/50)患者术后2年内死亡(TKA组无死亡)。
  • PFA组2%(1/50)患者术后1年后生病并拒绝继续参与(TKA组无此情况)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Controversy exists over the surgical treatment for severe patellofemoral osteoarthritis. We therefore wished to compare the outcome of patellofemoral arthroplasty (PFA) with TKA in a blinded randomized controlled trial. QUESTIONS/PURPOSES: In the first 2 years after surgery: (1) Does the overall gain in quality of life differ between the implants based on the area under the curve of patient-reported outcomes (PROs) versus time? (2) Do patients obtain a better quality of life at specific points in time after PFA than after TKA? (3) Do patients get a better range of movement after PFA than after TKA? (4) Does PFA result in more complications than TKA? METHODS: Patients were eligible if they had debilitating symptoms and isolated patellofemoral disease. One hundred patients were included from 2007 to 2014 and were randomized to PFA or TKA (blinded for the first year; blinded to patient, therapists, primary care physicians, etc; quasiblinded to assessor). Patients were seen for four clinical followups and completed six sets of questionnaires during the first 2 postoperative years. SF-36 bodily pain was the primary outcome. Other outcomes were range of movement, PROs (SF-36, Oxford Knee Score [OKS], Knee injury and Osteoarthritis Outcome Score [KOOS]) as well as complications and revisions. Four percent (two of 50) of patients died within the first 2 years in the PFA group (none in the TKA group), and 2% (one of 50) became ill and declined further participation after 1 year in the PFA group (none in the TKA group). The mean age at inclusion was 64 years (SD 8.9), and 77% (77 of 100) were women. RESULTS: The area under the curve (AUC) up to 2 years for SF-36 bodily pain of patients undergoing PFA and those undergoing TKA was 9.2 (SD 4.3) and 6.5 (SD 4.5) months, respectively (p = 0.008). The SF-36 physical functioning, KOOS symptoms, and OKS also showed a better AUC up to 2 years for PFA compared with TKA (6.6 [SD 4.8] versus 4.2 [SD 4.3] months, p = 0.028; 5.6 [SD 4.1] versus 2.8 [SD 4.5] months, p = 0.006; 7.5 [SD 2.7] versus 5.0 [SD 3.6] months, p = 0.001; respectively). The SF-36 bodily pain improvement at 6 months for patients undergoing PFA and those undergoing TKA was 38 (SD 24) and 27 (SD 23), respectively (p = 0.041), and at 2 years, the improvement was 39 (SD 24) and 33 (SD 22), respectively (p = 0.199). The KOOS symptoms improvement at 6 months for patients undergoing PFA and those undergoing TKA was 24 (SD 20) and 7 (SD 21), respectively (p < 0.001), and at 2 years, the improvement was 27 (SD 19) and 17 (SD 21), respectively (p = 0.023). Improvements from baseline for KOOS pain, SF-36 physical functioning, and OKS also differed in favor of PFA at 6 months, whereas only KOOS symptoms showed a difference between the groups at 2 years. No PRO dimension showed a difference in favor of TKA. At 4 months, 1 year, and 2 years, the ROM change from baseline for patients undergoing PFA and those undergoing TKA was (-7° [SD 13°] versus -18° [SD 14°], p < 0.001; -4° [SD 15°] versus -11° [SD 12°], p = 0.011; and -3° [SD 12°] versus -10° [SD 12°], p = 0.010). There was no difference in the number of complications. During the first 2 postoperative years, there were two revisions in patients undergoing PFA (one to a new PFA and one to a TKA). CONCLUSIONS: Patients undergoing PFA obtain a better overall knee-specific quality of life than patients undergoing TKA throughout the first 2 years after operation for isolated patellofemoral osteoarthritis. At 2 years, only KOOS function differs between patients undergoing PFA and those undergoing TKA, whereas other PRO dimensions do not show a difference between groups. The observations can be explained by patients undergoing PFA recovering faster than patients undergoing TKA and the functional outcome being better for patients undergoing PFA up to 9 months. Patients undergoing PFA regain their preoperative ROM, whereas patients undergoing TKA at 2 years have lost 10° of ROM. We found no differences in complications. LEVEL OF EVIDENCE: Level I, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Odgaard A, Madsen F, Kristensen PW, et al. The Mark Coventry Award: Patellofemoral Arthroplasty Results in Better Range of Movement and Early Patient-reported Outcomes Than TKA. Clin Orthop Relat Res. 2018. PMID: 29529622. doi:10.1007/s11999.0000000000000017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。